

Hepatitis C Treatment Update

Effective October 30, 2018, Jai Medical Systems will make Mavyret it's ONLY preferred treatment for Hepatitis C. Jai Medical Systems will continue to use the clinical criteria from Maryland Medicaid when approving treatment, but patients must be ineligible for the preferred treatment before a non-preferred treatment will be approved. Until then, requests for the previously preferred treatments Zepatier and Epclusa will still be reviewed without needing to establish ineligibility of Mavyret.

Additionally, under the new Maryland Medicaid criteria an exception of the fibrosis score rules can be made if the member has a viral condition which is known (documented to) result in an accelerated hepatic disease (fibrosis) progression and /or hepatic decompensation than what is normally expected from the course of chronic HCV, such as Hepatitis B or HIV. Recent (within 6 months of receipt of the request) viral loads for the coinfecting condition must be included and the viral load must be suppressed for the member to be approved. Per Maryland Medicaid criteria, suppression is defined as <200 copies/mL for HIV and <10 IU/mL for Hepatitis B.

Jai Medical Systems has updated its forms in order to reflect these changes. Older forms will still be accepted but all clinical information needed for the request must be included, even if there is no space for it on the form.

As a reminder, if the member has cirrhosis, the Child Pugh score must be included with any request for Mavyret, Vosevi, Epclusa, or Zepatier. Treatment Plan forms and Treatment Agreement forms are still required for all requests for Hepatitis C treatment.